Chimeric Antigen Receptor (CAR) T-cell Therapy

Activity description

This activity consists of recorded presentations from the "13th Annual Medical Director/Physician Leadership Forum" held in Austin, Texas, on May 15, 2019.

CAR T-cell therapy is a novel immuno-oncology treatment that has the potential to revolutionize cancer treatment, particularly for relapsed/refractory (R/R) malignancies. CAR T-cell therapy has demonstrated high response rates in R/R B-cell malignancies, which typically carry a poor prognosis and the area of CAR T-cell therapy is expected to expand quickly, with nearly 400 clinical trials ongoing around the world. While the majority of CAR T-cell therapy studies involve B-cell malignancies, this treatment is being investigated in solid tumors as well, such as triple-negative breast cancer.

While CAR T-cell therapy is highly effective against R/R malignancies, serious toxicities present an important treatment challenge, and no management guidelines or standardized approach for administering CAR T-cell therapy in adults currently exist. This presentation will discuss recommendations for patient selection for CAR T-cell therapy, along with its safety, efficacy, role and future strategies in cancer treatment.

Provided by
This activity is provided by OptumHealth Education.

Commercial support
There was no commercial support for this activity.

Required hardware/software
To view this activity, you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+ or Adobe Flash Player 9+. Be sure to disable any pop-up blocking software prior to beginning this activity.

Target Audience

This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals who are interested in CAR T-cell therapy.

Learning Objectives

At the end of this educational activity, participants should be able to:

  • Describe the safety, efficacy and role of CAR T-cell therapy in cancer treatment.
  • Outline guideline recommendations for patient selection, administration of treatment, and monitoring and management of toxicities with regard to CAR T-cell therapy in pediatric patients.
  • Discuss current and future strategies for applying CAR T-cell therapy and managing treatment-related complications in adults.

Additional Information

Activity summary
Available credit: 
  • 1.00 ACPE - Pharmacist
  • 1.00 ACPE - Pharmacy Technician
  • 1.00 AMA
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 CCMC - General
Activity opens: 
08/02/2019
Activity expires: 
08/02/2021
Rating: 
0

Faculty

Faculty Photo

Chimeric Antigen Receptor (CAR) T-cell Therapy
Matthew Lunning, DO
Assistant Professor, Internal Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, NE

Planning Committee

Sarah Chart, RN
Senior Director
OptumHealth Education
Eden Prairie, MN

Rebecca Gleason, RN, CCM
Activity Manager
OptumHealth Education
Eden Prairie, MN

Tina Rydland, PharmD
Crystal Clear Rx
Denver, CO

Crystal Wong, MD
President
Propoint Medical Writing
Wexford, PA

Disclosures of relevant financial relationships

In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education (OHE) requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services relate to the activity content. OHE ensures that the content is independent of commercial bias.

Dr. Lunning has indicated that he has received grant/research support from Celgene, Curis, Janssen, Juno Therapeutics, MiRagen and TG Therapeutics; and is a consultant for AbbVie, Bayer, Celgene, DAVA, Gilead Sciences, Janssen, Juno Therapeutics, Kite, Novartis, Onclive, Portola, Seattle Genetics, Spectrum, TG Therapeutics, VANIUM, Verastem.

Ms. Chart and Ms. Gleason have indicated that they are employees of and own stock in UnitedHealth Group.

Dr. Wong has indicated that she has received grant/research support from MyoKardia.

The remaining activity planner has no financial relationships to disclose.

Method for calculating CE credit
CE credit was calculated by the complexity of content.

Accreditation Statement
Joint Accreditation LogoIn support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.


Credit Designation Statements
Nurses
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.

Nurse practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.

Pharmacists/Pharmacy technicians
This activity is approved for 1.00 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour(s).
Unique Activity Number(s): JA0007123-0000-19-155-H01-P/T

Physicians
OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PAs
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.

Case managers
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hour(s) for Certified Case Managers (CCM).

Attendance
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.

Available Credit

  • 1.00 ACPE - Pharmacist
  • 1.00 ACPE - Pharmacy Technician
  • 1.00 AMA
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 CCMC - General

Accreditation Period

Activity opens: 
08/02/2019
Activity expires: 
08/02/2021
Please login to register.

You must be logged into your account to participate in this activity. Get started by clicking “Begin/Continue” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account”, “My Activities.”